Gempharmatech Co. Ltd. A (688046.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005964

Price
30.86 CNY
Market cap
12.65 bn CNY
P/E (2025)
88.71
P/S (2025)
15.95
Dividend yield
1.13 %
Net margin
17.98 %
Return on equity (ROE)
6.40 %
Return on assets (ROA)
4.98 %

Gempharmatech Co. Ltd. A financials

Fiscal year20242025
Revenue686.84 m CNY793.39 m CNY
Gross profit425.78 m CNY508.96 m CNY
Operating income122.35 m CNY181.99 m CNY
EBIT123.52 m CNY171.00 m CNY
Net income109.82 m CNY142.64 m CNY
Diluted EPS – continuing operations0.27 CNY0.35 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Gempharmatech Co. Ltd. A

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company has a strategic alliance with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies. The company was founded in 2017 and is headquartered in Nanjing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.